World Library  
Flag as Inappropriate
Email this Article

Gevotroline

Article Id: WHEBN0026908458
Reproduction Date:

Title: Gevotroline  
Author: World Heritage Encyclopedia
Language: English
Subject: Blonanserin, MDMA, Desmethylclozapine, List of dopaminergic drugs, AS-8112
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Gevotroline

Gevotroline
Systematic (IUPAC) name
8-fluoro-2-[3-(pyridin-3-yl)propyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
Clinical data
Legal status
  • Uncontrolled
Routes Oral
Identifiers
CAS number
ATC code None
PubChem
ChemSpider
UNII  YesY
Chemical data
Formula C19H20FN3 
Mol. mass 309.38 g/mol

Gevotroline (WY-47,384) is an atypical antipsychotic with a tricyclic structure which was under development for the treatment of schizophrenia by Wyeth-Ayerst.[1][2][3] It acts as a balanced, modest affinity D2 and 5-HT2 receptor antagonist and also possesses high affinity for the sigma receptor.[2][4][5][6] It was well-tolerated and showed efficacy in phase II clinical trials but was never marketed.[2][3]

Synthesis

Gevotroline synthesis:[7]

Lednicer drew it without the fluorine in his book. I simply copied what he did that is why no fluorine above.

See also

References

  1. ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC.  
  2. ^ a b c Bristol, James A. (1990). Annual Reports in Medicinal Chemistry (Volume 25). Boston: Academic Press.  
  3. ^ a b Stone, T. W.; Stone, Trevor (1996). CNS neurotransmitters and neuromodulators: dopamine. Boca Raton: CRC Press.  
  4. ^ Snyder SH, Largent BL (1989). "Receptor mechanisms in antipsychotic drug action: focus on sigma receptors". The Journal of Neuropsychiatry and Clinical Neurosciences 1 (1): 7–15.  
  5. ^ Matheson GK, Guthrie D, Bauer C, Knowles A, White G, Ruston C (January 1991). "Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat". Neuropharmacology 30 (1): 79–87.  
  6. ^ Gudelsky GA, Nash JF (February 1992). "Neuroendocrinological and neurochemical effects of sigma ligands". Neuropharmacology 31 (2): 157–62.  
  7. ^ Abou-Gharbia, Magid; Patel, Usha R.; Webb, Michael B.; Moyer, John A.; Andree, Terrance H.; Muth, Eric A. (1987). "Antipsychotic activity of substituted .gamma.-carbolines". Journal of Medicinal Chemistry 30 (10): 1818–23.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.